A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication
| Status: | Completed |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/2/2016 |
| Start Date: | March 2009 |
| End Date: | July 2012 |
| Contact: | David E Barker, MD |
| Email: | dbarker@corecenter.org |
| Phone: | 312-572-4503 |
A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication
The investigators seek to determine whether Virco®TYPE HIV-1 provides benefits equivalent to
those provided by local expert review. The investigators propose that clinic patients of the
Ruth M. Rothstein CORE Center who are having genotypic testing performed will be randomized
in a 1:1 fashion to local expert review and to Virco®TYPE HIV-1. Results of either method
will be shared with primary HIV care providers. Patient outcomes will be reviewed at a time
point equal to or greater than 2 months and 6 months following the change in antiretroviral
medications following the testing
those provided by local expert review. The investigators propose that clinic patients of the
Ruth M. Rothstein CORE Center who are having genotypic testing performed will be randomized
in a 1:1 fashion to local expert review and to Virco®TYPE HIV-1. Results of either method
will be shared with primary HIV care providers. Patient outcomes will be reviewed at a time
point equal to or greater than 2 months and 6 months following the change in antiretroviral
medications following the testing
Patients having some documented genotypic HIV resistance but having more than one fully
active medication will be randomized to either local review or algorithmic review by
VircoType HIV-1.
active medication will be randomized to either local review or algorithmic review by
VircoType HIV-1.
Inclusion Criteria:
- HIV resistance testing that demonstrates resistance to at least one drug
- Patients of the CORE Center, Chicago Illinois
Exclusion Criteria:
- Wild type HIV on resistance testing or less than or equal to one active
antiretroviral medication
We found this trial at
1
site
Click here to add this to my saved trials
